G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key...

More details

GPCRs with mAb or peptide-based therapeutics might have a great therapeutic potential in a variety of diseases, including cancer, inflammatory disorders, neurological and ...

More details

GPCR-targeted MTDLs have shown potentials in treating complex diseases and have become desirable targets for developing multi-target-directed ligands (MTDLs) because of ...

More details

About US

G protein-coupled receptors (GPCRs) represent important drug targets, as they regulate pivotal physiological processes and they have proved to be readily druggable.

Ackyee employs Deep Learning and Blockchain technology to create GPCRMIDAS, GPCROmics and GPCRMTDL , drug discovery platforms collaborating with YVBioMedical and YVLabs as well as strategic partners (Contract Research Organizations (CRO) and University Research Labs in US, Hong Kong and Europe).

Ackyee will focus on developing partnerships with pharmaceutical companies and Biotech companies providing Computational Biology and Chemistry Consulting Services.

Our Platforms

Ackyee scientific team created GPCRMIDAs, GPCRomics and GPCRMTDL platforms for the purpose of integrating systems biology, medicinal chemistry, biophysics, deep learning and blockchain technology to fine-tune proposed compounds and address challenging problems across the drug discovery life cycle of G-protein-coupled receptors (GPCR’s) Drug Design and Discovery. It also serves to predict the structure of proteins, scan through databases of potential molecules to find some that best fit a particular biological target in order to cure different oncological, neurological and metabolic disorders.

GPCR

Molecular Identification Design and Structure

G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key physiological effects. GPCR structural biology range from classes A, B, C, and F with small-molecule as allosteric modulators. GPCRMIDAS is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology to focus on GPCR-targeted Small Molecules

GPCRomics

Computational Biologics Discovery

GPCRs with mAb or peptide-based therapeutics might have a great therapeutic potential in a variety of diseases, including cancer, inflammatory disorders, neurological and metabolic diseases GPCRomics is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology to focus on GPCR-targeted biologics

GPCR MTDL

Multi-Target Directed Ligands

GPCR-targeted MTDLs have shown potentials in treating complex diseases and have become desirable targets for developing multi-target-directed ligands (MTDLs) because of their crucial roles in the pathophysiology of various human diseases and the accessibility of druggable sites at the cell surface. GPCRMTDL is a proprietary AI-Enabled Drug Discovery platform that incorporates Deep Learning and Blockchain technology

PIPELINE

So far, we have few drugs in pipelines that target either Neurological, Metabolic or Oncological GPCRs to combat various life-threatening diseases.

These are subtype selective small molecules that focused on targeting allosteric sites of neurological GPCRs as a mean to develop allosteric modulators to combat neurodegenerative diseases.

  • Target: Neuro-degenerative diseases
  • Mode of Action: Allosteric modulator
  • Discovery Stage:Pre-Clinical, Experimental discover

These ligands interact with both the orthosteric and allosteric site and utilizes their ability to introduce specific beneficial therapeutic effects for neurological disorders like psychosis and schizophrenia.

  • Target: Psychosis and schizophrenia
  • Mode of Action: Allosteric modulator
  • Discovery Stage: Pre-Clinical, Experimental discover

These compounds are highly specific to metabolic GPCRs which utilizes Glucose-stimulated insulin secretion (GSIS) pathway that eventually helps to regulate the activity of numerous neurotransmitters, hormones and paracrine factors.

  • Target: Metabolic Disorders
  • Mode of Action: Allosteric modulator
  • Discovery Stage: Pre-Clinical, Experimental discover

These compounds bind with the orthosteric or allosteric sites of a subfamily of oncological GPCR membrane proteins which has promising role in cancer prevention, metastasis and resistance.

  • Target: Oncological Disorders
  • Mode of Action: Antagonist
  • Discovery Stage: Pre-Clinical, Computational discovery

Portfolio

Rethinking GPCR Drug Discovery in the Artificial Intelligence and Blockchain era

At Ackyee, our multi-faceted approach to building value starts from our outstanding AI-Enabled Drug Discovery platform technology, our stellar team and a growing proprietary pipeline of novel drug candidates.

Neurolics

Neurolics is a business unit of Ackyee whose mission is to develop a pipeline of small molecules that focuse on targeting allosteric sites of neurological GPCRs as a mean to develop allosteric modulators to combat neurodegenerative diseases.

Oxia Bioscience

Oxia Bioscience is a business unit of Ackyee with the mission of building a pipeline of small molecule compounds that bind with the orthosteric or allosteric sites of a subfamily of oncological GPCR membrane proteins which has promising role in cancer prevention, metastasis and resistance.

Xudiera

Xudiera is a business unit of Ackyee with the mission of building a pipeline of small molecules that interact with both orthosteric and allosteric site and utilizes their ability to introduce specific beneficial therapeutic effects for neurological disorders like psychosis and schizophrenia.

Zymetics

Zymetics is a business unit of Ackyee with the mission of developing a pipeline of small molecules highly specific to metabolic GPCRs that utilizes Glucose-stimulated insulin secretion (GSIS) pathway which eventually helps to regulate the activity of numerous neurotransmitters, hormones and paracrine factors.

Partners

During our journey to find new potent and effective Drugs against GPCRs, we have established number of collaborations or partnerships with Research organizations, Biotech/pharmaceutical companies and academic collaborations.

Joint Venture Partnership

Ackyee growing portfolio of emerging joint venture companies headquartered in Asia will focus on GPCR Target discovery in CNS, Metabolic and Oncology diseases.

Product Development

Ackyee Scientific team that is responsible for product development collaborates with Wuxi Apptec who provides Scientific is a Clinical Research Organization (CRO) with a focus of providing Trial Design, Statistical Analysis & Consulting, and Data Management of GPCR Target identification, validation and more.

Research Partnership

Ackyee Scientific team collaborates with Università degli Studi dell'Aa for.

Our Team

We are not a team because we work together, we are a team because we respect, trust and care for each other.

Sehrish Naz, Ph.D

Interim

CEO

Nabila Berrabia

Interim

Chief Product Officer

Victor Adediwura

Research Scientist

Mohit Sharma, Ph.D

Research Scientist

Mario Rossi, PhD

Scientific Advisor

Pamela Garzone, Ph.D

Clinical Advisor

Girinath Pillai Ph.D

Advisor -Drug Discovery Platform

Ghassan Hadj Ahmed

Director Platform Development

Noureddine Boumahdi

Director Platform Development

Contact US

Your Message